GRI Bio (GRI) Revenue & Revenue Breakdown
GRI Bio Revenue Highlights
00
GRI Bio Revenue by Period
GRI Bio Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | -100.00% |
2020-12-31 | $100.00K | 100.00% |
2019-12-31 | - | - |
GRI Bio Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-07-31 | - | 100.00% |
2024-04-30 | - | -100.00% |
2024-01-31 | $5.39M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | - |
GRI Bio Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
IKNA | Ikena Oncology | $9.16M | - |
GBIO | Generation Bio | $5.90M | $4.09M |
CUE | Cue Biopharma | $5.49M | $3.34M |
HCWB | HCW Biologics | $2.84M | $426.42K |
STTK | Shattuck Labs | $1.66M | $1.61M |
ANEB | Anebulo Pharmaceuticals | - | - |
DSGN | Design Therapeutics | - | - |
GRI | GRI Bio | - | - |
CCCC | C4 Therapeutics | - | - |
AVTE | Aerovate Therapeutics | - | - |
CNTB | Connect Biopharma | - | - |
PASG | Passage Bio | - | - |
PRLD | Prelude Therapeutics | - | - |
CELC | Celcuity | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
EWTX | Edgewise Therapeutics | - | - |
XLO | Xilio Therapeutics | - | $2.36M |